NEW YORK (GenomeWeb) – Roche today announced that the Global Fund has selected the company as a supplier of early infant and viral load HIV diagnostics.

Roche will supply two tests, both of which use a dual-target design to amplify and detect two regions of the HIV-1 genome not subject to selective drug pressure, the firm said in a statement.

The cobas AmpliPrep/cobas TaqMan HIV-1 Test v2.0 detects group M and O strains of HIV-1 and has a broad dynamic range for viral load monitoring. The test runs on the firm's fully automated real-time PCR platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.